Patents by Inventor Phil Watson

Phil Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-transglutaminase 2 antibodies
    Patent number: 11718686
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: August 8, 2023
    Assignee: LIFEARC
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown
  • Anti-Transglutaminase 2 Antibodies
    Publication number: 20210101999
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 8, 2021
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown
  • Anti-transglutaminase 2 antibodies
    Patent number: 10961319
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 30, 2021
    Assignee: LIFEARC
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown
  • Anti-Transglutaminase 2 Antibodies
    Publication number: 20180355060
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Application
    Filed: May 23, 2018
    Publication date: December 13, 2018
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown
  • Anti-transglutaminase 2 antibodies
    Patent number: 10005846
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: June 26, 2018
    Assignee: LifeArc
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown
  • ANTI-TRANSGLUTAMINASE 2 ANTIBODIES
    Publication number: 20150218289
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Application
    Filed: May 24, 2013
    Publication date: August 6, 2015
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown